H-吴越投资2020-03-04 21:57
春节期间对血液灌流治疗进行初步研究,对采用全血灌流和血浆灌流的产品做了一些疏理,附以我个人的一些理解。相关公司列表如下:
表一、血浆吸附:
注:
(1)血浆吸附模式提前将血液中的血细胞分离出来,吸附效率更佳,还可以避免或减少血液相容性问题。血液相容性可能是因为离子树脂...查看全文
$Cytosorbents(CTSO)$ 8-K Current report, items 2.02, 8.01, and 9.01 Accession Number: 0001104659-20-084873 Act: 34 Size: 83 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-20-076935 Act: 34 Size: 56 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-20-072434 Act: 34 Size: 57 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, item 5.07 Accession Number: 0001104659-20-069510 Act: 34 Size: 29 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-20-060203 Act: 34 Size: 58 KB 网页链接
$Cytosorbents(CTSO)$ 内部交易: 2020-05-05,CEO,Chan Phillip P. ,期权,14100普通股, $9.39
$Cytosorbents(CTSO)$ 内部交易: 2020-05-05,总裁 and COO,Capponi Vincent ,期权,10123普通股, $9.26
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-058217 Size: 8 KB 网页链接
$Cytosorbents(CTSO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-058219 Size: 8 KB 网页链接
$Cytosorbents(CTSO)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-20-056970 Act: 34 Size: 137 KB 网页链接